Paper Review Records
All Paper Review Records
20 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
An Early Value Assessment of Biomarker-Guided Precision Medicine for Treatment-Resistant Hypertension: A Headroom and Threshold Analysis
Teebah Abu-Zahra; Sabine Grimm; Mirre Scholte; Ana I. Casas; Peter Saliba-Gustafsson; Paolo Parini; Manuela JooreShow moreShow less
1. Department of Clinical Epidemiology & Medical Technology Assessment (KEMTA), Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands; 2. Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands; 3. Departments of Medical Imaging and IQ health, Radboudumc, Nijmegen, The Netherlands; 4. Department of Neurology and Center for Translational Neuro- and Behavioural Sciences (C-TNBS), Clinic for Neurology, University Hospital Essen, Essen, Germany; 5. Cardio Metabolic Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; 6. Medicine Unit of Endocrinology, Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, Sweden; 7. Cardio Metabolic Unit, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, SwedenShow moreShow less
A Practical Framework for Understanding Cost-Effectiveness and Decision Risk in Health Benefits Package Design
Cassandra Nemzoff; Sabine Grimm; Manuela Joore; Andres Madriz-Montero; Stella Matutina Umuhoza; James Humuza; Sedona Sweeney; Rob Baltussen; Anna VassallShow moreShow less
1. Department of Global Health, London School of Hygiene and Tropical Medicine, London, UK; 2. Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre+, Maastricht, Netherlands; 3. Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, Netherlands; 4. School of Public Health, University of Rwanda, Kigali, Rwanda; 5. Radboud University Medical Center, Nijmegen, NetherlandsShow moreShow less
Spillover Effects of Medical Innovations: A Universal and Scalable Approach to Measure the Societal Value of Avoided Informal Care Time
Rebecca Grün; Diego Hernandez; Adnan Atitallah; Platon Peristeris; Lena Steinbeck; Eva Levi,; Malina MüllerShow moreShow less
1. Department of Health Economics, WifOR Institute, Darmstadt, Germany; 2. Department of Health Economics, WifOR Institute, Athens, Greece; 3. Die Senatorin für Gesundheit, Frauen und Verbraucherschutz Bremen, Bremen, GermanyShow moreShow less
Estimating the Share of Social Surplus Generated by Pharmaceutical Innovation Accruing to Manufacturers: A Systematic Literature Review
Robert J. Nordyke; Tyler D. Wagner; Janine Ross; Sreeranjani Menon; Jonathan D. CampbellShow moreShow less
1. Beta6 Consulting, Topanga, United States; 2. National Pharmaceutical Council, Washington, USA; 3. Petauri Evidence, York, England; 4. Massachusetts College of Pharmacy and Health Sciences, Boston, USAShow moreShow less
Evaluating Mongolia’s Sugar-Sweetened Beverage Tax: A Cost-Effectiveness Analysis
Nyamdavaa Byambadorj; Rohan Best; Undram Mandakh; Kompal SinhaShow moreShow less
1. Department of Economics, Macquarie Business School, Macquarie University, Sydney, Australia; 2. Department of Family Medicine, School of Medicine, Mongolian National University of Medical Science, Ulaanbaatar, MongoliaShow moreShow less
Cost-Effectiveness of Adult Hepatitis A Vaccination Strategies in Korea Under an Aging Susceptibility Profile
Yuna Lim; Gerardo Chowell; Eunok JungShow moreShow less
1. Department of Mathematics, Konkuk University, Seoul, Republic of Korea; 2. Department of Population Health Sciences, Georgia State University, Atlanta, USA; 3. Department of Applied Mathematics, Kyung Hee University, Yongin, Republic of KoreaShow moreShow less
FAQ
How long does Applied Health Economics and Health Policy take to review a manuscript?
As of 2026-11-18, CrushSCI has 20 complete review records for Applied Health Economics and Health Policy. The fastest paper went from submission to acceptance in 87 days (Cost Effectiveness of Endovascular Thrombectomy for Large Ischemic Strokes: A US Healthcare Payer Markov Model Informed by Randomized Trials, received 2026-01-03, accepted 2026-03-31); the slowest took 367 days. The average is 193.3 days and the median is 175.5 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
